KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Halozyme Therapeutics (HALO) over the last 17 years, with Q3 2025 value amounting to $1.49.

  • Halozyme Therapeutics' EPS (Basic) rose 3796.3% to $1.49 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.89, marking a year-over-year increase of 5928.34%. This contributed to the annual value of $3.5 for FY2024, which is 6439.2% up from last year.
  • According to the latest figures from Q3 2025, Halozyme Therapeutics' EPS (Basic) is $1.49, which was up 3796.3% from $1.36 recorded in Q2 2025.
  • Halozyme Therapeutics' EPS (Basic)'s 5-year high stood at $1.53 during Q3 2021, with a 5-year trough of $0.16 in Q2 2022.
  • Moreover, its 5-year median value for EPS (Basic) was $0.62 (2023), whereas its average is $0.72.
  • Its EPS (Basic) has fluctuated over the past 5 years, first skyrocketed by 60000.0% in 2021, then plummeted by 7500.0% in 2022.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' EPS (Basic) stood at $0.47 in 2021, then dropped by 8.51% to $0.43 in 2022, then soared by 51.16% to $0.65 in 2023, then skyrocketed by 66.2% to $1.08 in 2024, then surged by 37.92% to $1.49 in 2025.
  • Its EPS (Basic) was $1.49 in Q3 2025, compared to $1.36 in Q2 2025 and $0.96 in Q1 2025.